Editorial: Itch treatments
<p dir="ltr">Similar to pain, pruritus (itch) is a very common somato-sensory sensation that almost everyone experiences in their lifetime. Once dysregulated, pruritus can become chronic and debilitating, significantly affecting a patient's and their family's quality of lif...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <p dir="ltr">Similar to pain, pruritus (itch) is a very common somato-sensory sensation that almost everyone experiences in their lifetime. Once dysregulated, pruritus can become chronic and debilitating, significantly affecting a patient's and their family's quality of life (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B1" target="_blank">1</a>). Molecular biology and translational research have helped to better identify and understand the molecular mechanisms of the various pathways of histamine-dependent and -independent itch and supported the development of new treatment options for the different subtypes of pruritic diseases, whether inflammatory or non-inflammatory, neurologic or neuropathic, for example (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B2" target="_blank">2</a>–<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B6" target="_blank">6</a>). Furthermore, to identify the cellular mechanisms that differentiate and specify the different itch pathways in the various pruritic diseases is critical (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B7" target="_blank">7</a>). The treatment options for CP span a number of topical and systemic medications as well as phototherapy, depending on the underlying disease, age, and comorbidities (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B8" target="_blank">8</a>, <a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B9" target="_blank">9</a>). Even in pruritus of unknown origin, the anti-IL-4 receptor-a antibody dupilumab has been shown to be effective, at least in a case report, suggesting that cytokines and microinflammation play a role in presumptive “non-inflammatory” conditions to a larger extent than anticipated (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B1" target="_blank">1</a>, <a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B6" target="_blank">6</a>). However, neuro-modulatory agents are still necessary in various pruritic diseases, especially to treat neuropathic pruritus (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B2" target="_blank">2</a>, <a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B5" target="_blank">5</a>) or prurigo (<a href="https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1373702/full#B7" target="_blank">7</a>). Here, extensive translational and clinical studies are necessary to stratify the best treatment.</p><h2>Other Information</h2><p dir="ltr">Published in: Frontiers in Medicine<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3389/fmed.2024.1373702" target="_blank">https://dx.doi.org/10.3389/fmed.2024.1373702</a></p> |
|---|